$0.55
2.21%
Nasdaq, Nov 06, 04:25 pm EST. Closed.
ISIN
US17322U2078
Symbol
CTXR

Citius Pharmaceuticals Inc Stock price

$0.55
+0.06 13.40% 1M
-0.12 18.20% 6M
-0.23 29.85% YTD
-0.69 56.04% 1Y
-18.70 97.17% 3Y
-47.70 98.87% 5Y
-186.95 99.71% 10Y
-374.45 99.85% 20Y
Nasdaq, Closing price Fri, Nov 06 2026
-0.01 2.21%
ISIN
US17322U2078
Symbol
CTXR
Industry

Is Citius Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,093 stocks worldwide.

Key metrics

Basic
Market capitalization
$15.3m
Enterprise Value
$4.7m
Net debt
positive
Cash
$17.0m
Shares outstanding
27.5m
Valuation
P/E
negative
P/S | estimate
2.2 | 1.5
EV/Sales | estimate
0.7 | 0.5
EV/FCF | ex SBC
negative | negative
P/B
0.2
Financial Health
Equity Ratio
51.6%
Return on Equity
-55.4%
ROCE
-67.7%
ROIC
-60.6%
Debt/Equity
0.1
Share-Based Compensation & Dilution
SBC | % of Revenue
$14.8m | 207.7%
SBC as % of FCF
-
SBC Growth 1Y
39.5%
Share Count Growth 1Y
96.1%
Shareholder Yield
-96.1%
Financials
Revenue | estimate
$7.1m | $10.3m
EBITDA
$-57.4m
EBIT
$-61.4m
Net Income
$-46.3m
Free Cash Flow | ex SBC
$-47.3m | $-62.1m
Growth
Revenue | estimate
- | -
EBITDA
-41.3%
EBIT
-50.5%
Net Income
-11.3%
Free Cash Flow
-125.2%
Margin
Gross
77.3%
EBITDA
-807.4%
EBIT
-863.9%
Net
-651.3%
Free Cash Flow | ex SBC
-665.6% | -873.4%
More
EPS
$-1.8
FCF per Share
$-1.7
Short interest
21.1%
Employees
23
Rev per Employee
$0.0

Citius Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Citius Pharmaceuticals Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Citius Pharmaceuticals Inc forecast:

Buy
86%
Hold
14%

Financial data from Citius Pharmaceuticals Inc

Jun '26
+/-
%
7.11 7.11
-
100%
- Direct Costs 1.61 1.61
-
23%
5.50 5.50
-
77%
- Selling and Administrative Expenses 57 57
85% 85%
801%
- Research and Development Expense 5.93 5.93
43% 43%
83%
-57 -57
41% 41%
-807%
- Depreciation and Amortization 4.01 4.01
1,905% 1,905%
56%
EBIT (Operating Income) EBIT -61 -61
50% 50%
-863%
Net Profit -46 -46
11% 11%
-651%

In millions USD.

Don't miss a Thing! We will send you all news about Citius Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Citius Pharmaceuticals Inc Stock News

Neutral
PRNewsWire
●
2 days ago
Data featured in oral presentation at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) 2026 Annual Meeting in Berlin Patients who responded to LYMPHIR reported sustained improvement in skin-related quality of life measures CRANFORD, N.J., Nov. 4, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CT...
Neutral
PRNewsWire
●
11 days ago
CRANFORD, N.J., Oct. 26, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced preliminary, unaudited LYMPHIR® (denileukin diftitox-cxdl) unit sales to U.S. wholesalers and institutional vial order...
Neutral
PRNewsWire
●
3 months ago
$7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR ® launch progresses Strong institutional demand drives growth in total vials ordered and number of institutions ordering LYMPHIR ordered by 44 institutions since launch CRANFORD, N.J., Aug. 14, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), an oncology-focused biophar...
More Citius Pharmaceuticals Inc News

Company Profile

Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

Head office United States
CEO Mr. Mazur
Employees 23
Founded 2007
Website www.citiuspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today